Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Urol
Main Authors: Koie, Takuya, Ohyama, Chikara, Yoneyama, Takahiro, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Hashimoto, Yasuhiro, Yoneyama, Tohru, Tobisawa, Yuki, Mori, Kazuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417199/
https://ncbi.nlm.nih.gov/pubmed/25887125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-015-0027-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados